PTCH1 is altered in 3.0% of malignant solid tumor patients with PTCH1 Mutation present in 2.39% of all malignant solid tumor patients [4].

PTCH1 Mutation is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain PTCH1 Mutation and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [5].

PTCH1 is altered in 5.54% of melanoma patients with PTCH1 Mutation present in 5.18% of all melanoma patients [4].

PTCH1 Mutation is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

PTCH1 is altered in 3.65% of glioblastoma patients with PTCH1 Mutation present in 3.14% of all glioblastoma patients [4].

PTCH1 Mutation is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 Mutation and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [5].

PTCH1 is altered in 2.76% of non-small cell lung carcinoma patients with PTCH1 Mutation present in 2.56% of all non-small cell lung carcinoma patients [4].

PTCH1 Mutation is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 Mutation and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

PTCH1 is altered in 3.16% of bladder carcinoma patients with PTCH1 Mutation present in 2.47% of all bladder carcinoma patients [4].

PTCH1 Mutation is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

PTCH1 is altered in 2.55% of anaplastic astrocytoma patients with PTCH1 Mutation present in 2.27% of all anaplastic astrocytoma patients [4].

PTCH1 Mutation is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 Mutation and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [5].

PTCH1 is altered in 1.59% of pancreatic carcinoma patients with PTCH1 Mutation present in 1.55% of all pancreatic carcinoma patients [4].

PTCH1 Mutation is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

PTCH1 is altered in 81.03% of basal cell carcinoma patients with PTCH1 Mutation present in 46.55% of all basal cell carcinoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for basal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and basal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 is altered in 16.77% of medulloblastoma patients with PTCH1 Mutation present in 10.56% of all medulloblastoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 is altered in 13.48% of central nervous system embryonal neoplasm patients with PTCH1 Mutation present in 8.7% of all central nervous system embryonal neoplasm patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for central nervous system embryonal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 is altered in 5.0% of anaplastic pleomorphic xanthoastrocytoma patients with PTCH1 Mutation present in 5.0% of all anaplastic pleomorphic xanthoastrocytoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 is altered in 4.97% of anaplastic oligodendroglioma patients with PTCH1 Mutation present in 4.97% of all anaplastic oligodendroglioma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 is altered in 3.51% of anaplastic ependymoma patients with PTCH1 Mutation present in 3.51% of all anaplastic ependymoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 is altered in 4.85% of colorectal carcinoma patients with PTCH1 Mutation present in 3.39% of all colorectal carcinoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PTCH1 is altered in 3.26% of high-grade glioma, NOS patients with PTCH1 Mutation present in 3.26% of all high-grade glioma, NOS patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 is altered in 3.57% of malignant glioma patients with PTCH1 Mutation present in 3.16% of all malignant glioma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 is altered in 3.4% of diffuse glioma patients with PTCH1 Mutation present in 3.0% of all diffuse glioma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 is altered in 2.62% of head and neck carcinoma patients with PTCH1 Mutation present in 2.22% of all head and neck carcinoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PTCH1 is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients with PTCH1 Mutation present in 1.96% of all diffuse midline glioma, H3 K27M-mutant patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 is altered in 1.9% of multiple myeloma patients with PTCH1 Mutation present in 1.9% of all multiple myeloma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTCH1 is altered in 1.8% of breast carcinoma patients with PTCH1 Mutation present in 1.64% of all breast carcinoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PTCH1 is altered in 1.97% of ovarian carcinoma patients with PTCH1 Mutation present in 1.63% of all ovarian carcinoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PTCH1 is altered in 1.82% of sarcoma patients with PTCH1 Mutation present in 1.2% of all sarcoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PTCH1 is altered in 1.31% of B-cell non-hodgkin lymphoma patients with PTCH1 Mutation present in 1.13% of all B-cell non-hodgkin lymphoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTCH1 is altered in 1.24% of malignant salivary gland neoplasm patients with PTCH1 Mutation present in 1.06% of all malignant salivary gland neoplasm patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PTCH1 is altered in 1.27% of lymphoma patients with PTCH1 Mutation present in 1.01% of all lymphoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PTCH1 is altered in 1.14% of biliary tract carcinoma patients with PTCH1 Mutation present in 0.96% of all biliary tract carcinoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for central nervous system ganglioneuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for central nervous system neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 is altered in 1.35% of ependymoma patients [4].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, non-WNT/non-SHH, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, SHH-activated, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and medulloblastoma, SHH-activated as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, WNT-activated, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) [5].

PTCH1 Mutation is an inclusion criterion in 1 clinical trial for medulloepithelioma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 Mutation and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) [5].